{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:38:35Z","timestamp":1763105915156},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount for ALL chemotherapy, but additional money needed to treat any other unexpected condition should be taken from the budget of the oncologic healthcare providers. So the purpose of our study was to estimate and evaluate the direct medical costs associated to EAs during RICP in children with ALL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was retrospective, longitudinal, and observational based on medical records review of patients in RICP. The CTCAE was used to identify and classify AEs according to a SOC category. We focused on extracting resources data that were consumed both for inpatients and outpatients AEs. A micro-costing approach was adopted which involve quantification of each healthcare resource consumed by the hospital multiplying them by unit cost. The probability distributions of data were evaluated to identify the appropriated statistical tests to be used for comparisons between groups that were performed with Wilcoxon rank sum test. Generalized linear models (GLM) were adjusted to evaluate the effects of patient characteristics on total cost.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty patients accumulated 204 inpatient and 81 outpatient AEs during RICP. Comparison of total costs between groups showed an incremental cost of $7,460.23 likewise attributable to AEs. The total cost of a pediatric patient undergoing RICP without adverse events was $3,078.36 and the total cost of a patient with AEs exceeds it threefold.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The costs associated with AEs during RICP in Mexican children with ALL representing a high burden for the healthcare provider. Generalized linear models showed that variables such as sex, risk category and alive status are associated with the total costs of AEs. This is the first study aiming to analyze the effect of ALL-related AEs on health care costs in pediatric population, so our results may help not only to local decision making but also it may contribute to the research agenda in this field.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08676-x","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:03:08Z","timestamp":1671008588000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)"],"prefix":"10.1186","volume":"22","author":[{"given":"Er\u00e9ndira","family":"Mej\u00eda-Arangur\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Reyes-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Enrique","family":"Ju\u00e1rez-Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosef Olaf","family":"Hern\u00e1ndez-Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto Daniel","family":"Saucedo-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Hern\u00e1ndez-Pliego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mart\u00ednez-Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia A.","family":"Barajas-Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gardu\u00f1o-Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"issue":"9617","key":"8676_CR1","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(08)60457-2.","journal-title":"Lancet"},{"issue":"14","key":"8676_CR2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Bruce MC, Paul SG, et al. Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children\u2019s Oncology Group. J Clin Oncol. 2012;30(14):1663\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.8018.","journal-title":"J Clin Oncol"},{"key":"8676_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.seminhematol.2008.09.007","volume":"46","author":"M Stanulla","year":"2009","unstructured":"Stanulla M, Schrappe M. Treatment of Childhood Acute Lymphoblastic Leukemia. Semin Hematol. 2009;46:52\u201363. https:\/\/doi.org\/10.1053\/j.seminhematol.2008.09.007.","journal-title":"Semin Hematol"},{"key":"8676_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern Therapy of Acute Lymphoblastic Leukemia. J Clin Oncol. 2011;29:532\u201343. https:\/\/doi.org\/10.1200\/JCO.2010.30.1382.","journal-title":"J Clin Oncol"},{"key":"8676_CR5","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 31 May 2018."},{"key":"8676_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/pbc.24855","volume":"61","author":"AE Seif","year":"2014","unstructured":"Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YV, et al. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:846\u201352. https:\/\/doi.org\/10.1002\/pbc.24855.","journal-title":"Pediatr Blood Cancer"},{"key":"8676_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/576950","volume":"2015","author":"E Jim\u00e9nez-Hern\u00e1ndez","year":"2015","unstructured":"Jim\u00e9nez-Hern\u00e1ndez E, Jaimes-Reyes EZ, Arellano-Galindo J, Garc\u00eda-Jim\u00e9nez X, Tiznado-Garc\u00eda HM, Due\u00f1as-Gonz\u00e1lez MT, et al. Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00\u201301. Biomed Res Int. 2015;2015:1\u20139. https:\/\/doi.org\/10.1155\/2015\/576950.","journal-title":"Biomed Res Int"},{"key":"8676_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/08880010701774132","volume":"25","author":"R Rivera-Luna","year":"2008","unstructured":"Rivera-Luna R, Olaya-Vargas A, Vel\u00e1squez-Avi\u00f1a M, Frenk S, C\u00e1rdenas-Card\u00f3s R, Leal-Leal C, et al. Early death in children with acute lymphoblastic leukemia: Does malnutrition play a role? Pediatr Hematol Oncol. 2008;25:17\u201326. https:\/\/doi.org\/10.1080\/08880010701774132.","journal-title":"Pediatr Hematol Oncol"},{"key":"8676_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/sj.bjc.6604895","volume":"100","author":"S Gupta","year":"2009","unstructured":"Gupta S, Bonilla M, Fuentes SL, Caniza M, Howard SC, Barr R, et al. Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. Br J Cancer. 2009;100:1026\u201331. https:\/\/doi.org\/10.1038\/sj.bjc.6604895.","journal-title":"Br J Cancer"},{"key":"8676_CR10","first-page":"286","volume":"55","author":"M Aguilar-Hern\u00e1ndez","year":"2017","unstructured":"Aguilar-Hern\u00e1ndez M, Fern\u00e1ndez-Castillo G, N\u00fa\u00f1ez-Villegas NN, P\u00e9rez-Casillas RX, N\u00fa\u00f1ez-Enr\u00edquez JC. Principales causas de mortalidad durante la fase de inducci\u00f3n a la remisi\u00f3n en los pacientes pedi\u00e1tricos con leucemia linfobl\u00e1stica aguda. Rev Med Inst Mex Seguro Soc. 2017;55:286\u201391 https:\/\/www.medigraphic.com\/cgi-bin\/new\/resumen.cgi?IDARTICULO=72971. Accessed 01 June 2018.","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"8676_CR11","first-page":"218","volume":"69","author":"M Zapata-Tarr\u00e9s","year":"2012","unstructured":"Zapata-Tarr\u00e9s M, Kl\u00fcnder-Kl\u00fcnder M, Cicero-Oneto C, Rivera-Luna R, Velasco FO-R, Gallo GC, et al. An\u00e1lisis de la atenci\u00f3n de las complicaciones durante el tratamiento de ni\u00f1os con leucemia linfobl\u00e1stica aguda. Bol Med Hosp Infant Mex. 2012;69:218\u201325 https:\/\/www.medigraphic.com\/cgi-bin\/new\/resumen.cgi?IDARTICULO=35781. Accessed 01 June 2018.","journal-title":"Bol Med Hosp Infant Mex"},{"key":"8676_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2014-03-560847","volume":"124","author":"D O\u2019Connor","year":"2014","unstructured":"O\u2019Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014;124:1056\u201361. https:\/\/doi.org\/10.1182\/blood-2014-03-560847.","journal-title":"Blood"},{"key":"8676_CR13","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1200\/JCO.2004.01.191","volume":"22","author":"U Creutzig","year":"2004","unstructured":"Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384\u201393. https:\/\/doi.org\/10.1200\/JCO.2004.01.191.","journal-title":"J Clin Oncol"},{"key":"8676_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/CBO9780511977633","volume-title":"Childhood Leukemias. Third","author":"CH Pui","year":"2012","unstructured":"Pui CH. Childhood Leukemias. Third. New York: Cambridge University Press; 2012. p. 1\u2013562."},{"key":"8676_CR15","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","volume":"17","author":"K Schmiegelow","year":"2016","unstructured":"Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17:e231\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(16)30035-3.","journal-title":"Lancet Oncol"},{"key":"8676_CR16","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/pbc.25628","volume":"62","author":"KA Meeske","year":"2015","unstructured":"Meeske KA, Ji L, Freyer DR, Gaynon P, Ruccione K, Butturini A, et al. Comparative toxicity by sex among children treated for acute lymphoblastic leukemia: a report from the Children\u2019s oncology group. Pediatr Blood Cancer. 2015;62:2140\u20139. https:\/\/doi.org\/10.1002\/pbc.25628.","journal-title":"Pediatr Blood Cancer"},{"key":"8676_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/(sici)1097-0142(19971101)80:9<1717::aid-cncr4>3.0.co;2-b","volume":"80","author":"PS Gaynon","year":"1997","unstructured":"Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80:1717\u201326. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19971101)80:9%3c1717::aid-cncr4%3e3.0.co;2-b.","journal-title":"Cancer"},{"key":"8676_CR18","volume-title":"The chemotherapy source book. Fourth","author":"MC Perry","year":"2008","unstructured":"Perry MC. The chemotherapy source book. Fourth. Philadelphia: Lippincott Williams & Wilkins. Walters Kluwer Health; 2008."},{"key":"8676_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","volume":"14","author":"AM Saito","year":"2008","unstructured":"Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14:197\u2013207. https:\/\/doi.org\/10.1016\/j.bbmt.2007.10.010.","journal-title":"Biol Blood Marrow Transplant"},{"key":"8676_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14737167.2018.1490645","volume":"18","author":"X Zhang","year":"2018","unstructured":"Zhang X, Song X, Lopez-Gonzalez L, Jariwala-Parikh K, Cong Z. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 2018;18:573\u201380. https:\/\/doi.org\/10.1080\/14737167.2018.1490645.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"8676_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18553\/jmcp.2015.21.2.158","volume":"21","author":"B Arondekar","year":"2015","unstructured":"Arondekar B, Curkendall S, Monberg M, Mirakhur B, Oglesby AK, Lenhart GM, et al. Economic Burden Associated with Adverse Events in Patients with Metastatic Melanoma. J Manag Care Spec Pharm. 2015;21:158\u201364. https:\/\/doi.org\/10.18553\/jmcp.2015.21.2.158.","journal-title":"J Manag Care Spec Pharm"},{"key":"8676_CR22","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00228-013-1563-z","volume":"69","author":"LM Khan","year":"2013","unstructured":"Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay \u2013 a systematic review. Eur J Clin Pharmacol. 2013;69:1985\u201396. https:\/\/doi.org\/10.1007\/s00228-013-1563-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"8676_CR23","unstructured":"Word Health Organization. Model Formulary for children. Based on the second model list of essential medicines for children 2009, Genebra: WHO 2010, p. xiii. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44309\/9789241599320_eng.pdf"},{"key":"8676_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1651-2227.2000.tb00087.x","volume":"89","author":"J Rahiala","year":"2000","unstructured":"Rahiala J, Riikonen P, Kek\u00e4l\u00e4inen L, Perkki\u00f6 M. Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols. Acta Paediatr. 2000;89:482\u20137. https:\/\/doi.org\/10.1111\/j.1651-2227.2000.tb00087.x.","journal-title":"Acta Paediatr"},{"key":"8676_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/pbc.22127","volume":"53","author":"Y Liu","year":"2009","unstructured":"Liu Y, Chen J, Tang J, Ni S, Xue H, Pan C. Cost of childhood acute lymphoblastic leukemia care in Shanghai. China Pediatr Blood Cancer. 2009;53:557\u201362. https:\/\/doi.org\/10.1002\/pbc.22127.","journal-title":"China Pediatr Blood Cancer"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08676-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08676-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08676-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:06:34Z","timestamp":1671008794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08676-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8676"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08676-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical research committee of Hospital Infantil de M\u00e9xico Federico G\u00f3mez, reviewed the protocol and it was approved with the number HIM-DIC-SR-2020\u2013004 and indicated that this protocol was considered as a documentary research; therefore, it was not necessary to obtain informed consent from the patients. The participating investigators are obliged to protect the identity and personal data of the research subjects, both during the development of the protocol and in the phases of publication or dissemination of the results of the same.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1522"}}